

# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person* Cormack Scott Daniel			2. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) President and CEO		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/21/2008					
400-1001 W. BROADWAY			4. If Amendment, Date Original Filed(Month/Day/Year) 08/21/2008			6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(Street)								
VANCOUVER, A1 V6H 4B1								
(City)			(State)			(Zip)		

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		24,825 (2)		08/21/2008	01/01/2009	Common Stock	24,825	(3)	24,825	D	
Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		871 (4)		08/21/2008	08/01/2009	Common stock	871	(5)	871	I	By Spouse
Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		7,077 (6)		08/21/2008	02/01/2010	Common Stock	7,077	(7)	7,077	I	By Spouse
Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		20,470 (8)		08/21/2008	12/16/2010	Common Stock	20,470	(9)	20,470	D	
Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		6,533 (10)		08/21/2008	12/16/2010	Common stock	6,533	(11)	6,533	I	By Spouse
Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A		21,559 (12)		08/21/2008	01/14/2011	Common Stock	21,559	(13)	21,559	D	

Stock option (right to buy)	\$ 3.889 (1)	08/21/2008		A	6,859 (6)	08/21/2008	01/14/2011	Common Stock	6,859	(14)	6,859	I	By Spouse
Stock option (right to buy)	\$ 4.1051 (15)	08/21/2008		A	46,167 (16)	08/21/2008	08/08/2012	Common Stock	46,167	(17)	46,167	D	

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Cormack Scott Daniel 400-1001 W. BROADWAY VANCOUVER, A1 V6H 4B1	X		President and CEO	

## Signatures

Sandra Thomson as Attorney-in-fact for Scott Cormack		02/02/2009
<small>--Signature of Reporting Person</small>		<small>Date</small>

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Due to an administrative error, the original Form 4 overstated the exercise price by \$0.0025.
- (2) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 16.
- (3) Received in exchange for a stock option to acquire 114,000 shares of OncoGenex Technologies Inc. ("OncoGenex Technologies") common stock for CAD\$0.90 per share in connection with an arrangement between OncoGenex Technologies and OncoGenex Pharmaceuticals, Inc. (the "Arrangement").
- (4) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 1.
- (5) Received in the Arrangement in exchange for a stock option to acquire 4,000 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (6) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 4.
- (7) Received in the Arrangement in exchange for a stock option to acquire 32,500 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (8) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 13.
- (9) Received in the Arrangement in exchange for a stock option to acquire 94,000 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (10) Due to an administrative error, the original Form 4 overstated the number of shares subject to the stock option by 5.
- (11) Received in the Arrangement in exchange for a stock option to acquire 30,000 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (12) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 14.
- (13) Received in the Arrangement in exchange for a stock option to acquire 99,000 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (14) Received in the Arrangement in exchange for a stock option to acquire 31,500 shares of OncoGenex Technologies common stock for CAD\$0.90 per share.
- (15) Due to an administrative error, the original Form 4 overstated the exercise price by \$0.0026.
- (16) Due to an administrative error, the original Form 4 understated the number of shares subject to the stock option by 30.
- (17) Received in the Arrangement in exchange for a stock option to acquire 212,000 shares of OncoGenex Technologies common stock for CAD\$0.95 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.